Rivastigmine News
Dr. Reddy's Announces Settlement of Exelon (rivastigmine tartrate) ANDA Litigation With Novartis
Dr. Reddy's Laboratories (NYSE:RDY) today announced that it has entered into a settlement agreement with Novartis Pharma AG which involves a stipulation of dismissal of the lawsuits in the United States relating to the...
Novartis Exelon patch gets EU nod for Alzheimer's
The European Union has approved Novartis's Exelon skin patch to treat Alzheimer's disease, the Swiss drugmaker said on Monday.
First and only skin patch for mild to moderate Alzheimer's disease is approved in the U.S.
For the first time, people suffering from mild to moderate Alzheimer's disease have a transdermal patch treatment option.
SCOLR Announces Completion of 12 hour CDT-Pseudoephedrine ANDA Registration Batches, New Drug Development Targets
SCOLR Pharma, Inc. (Amex: DDD) announced today that its contract manufacturing partner, Cardinal Healthcare, has produced batches of SCOLR's 12 hour CDT-based pseudoephedrine tablets needed for the completion of its Abbreviated...
Few Alzheimer's treatments now and no cure ... yet
When a person is diagnosed with Alzheimer’s disease, the prognosis is not a good one.